The currently running clinical study NCT02776917 is evaluating the combined treatment of Cirmtuzumab, a monoclonal antibody directed against the ROR1 (receptor-tyrosine-kinase like orphan receptor 1), with PTX, in 22 patients with unresectable BC, metastatic or locally advanced. This evidence concerns the gene ROR1 and breast cancer.